Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Mylan Labs

Pharmaceutical intelligence for Mylan Labs with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Assets
1

Recent signals(6)

RegulatoryAugust 6, 2026

FDA Approves Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has approved the application ANDA218364 for levetiracetam in sodium chloride submitted by Mylan Labs.

RegulatoryJuly 27, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted a supplemental application for Zoledronic Acid submitted by Mylan Labs.

RegulatoryJuly 24, 2026

FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs

The FDA has granted approval for Ferric Carboxymaltose under application ANDA212572 submitted by Mylan Labs.

RegulatoryJuly 14, 2026

FDA Grants Approval for Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has granted approval for Mylan Labs' ANDA218364, a formulation of levetiracetam in sodium chloride.

RegulatoryJuly 4, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted the supplemental application ANDA205254 for Zoledronic Acid submitted by Mylan Labs.

RegulatoryJuly 1, 2026

FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs

The FDA has approved the Abbreviated New Drug Application (ANDA) for Ferric Carboxymaltose submitted by Mylan Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(6)

RegulatoryAugust 6, 2026

FDA Approves Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has approved the application ANDA218364 for levetiracetam in sodium chloride submitted by Mylan Labs.

RegulatoryJuly 27, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted a supplemental application for Zoledronic Acid submitted by Mylan Labs.

RegulatoryJuly 24, 2026

FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs

The FDA has granted approval for Ferric Carboxymaltose under application ANDA212572 submitted by Mylan Labs.

RegulatoryJuly 14, 2026

FDA Grants Approval for Levetiracetam in Sodium Chloride by Mylan Labs

The FDA has granted approval for Mylan Labs' ANDA218364, a formulation of levetiracetam in sodium chloride.

RegulatoryJuly 4, 2026

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted the supplemental application ANDA205254 for Zoledronic Acid submitted by Mylan Labs.

RegulatoryJuly 1, 2026

FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs

The FDA has approved the Abbreviated New Drug Application (ANDA) for Ferric Carboxymaltose submitted by Mylan Labs.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

FDA →

Therapeutic areas

Antiepileptic →
Bone Health →
Hematology →
Iron Deficiency Anemia →
Neurology →
Oncology →

Indications

Iron Deficiency Anemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.